
Recent data has revealed the live attenuated influenza vaccine (LAIV), also known as the “nasal spray” vaccine, to be grossly ineffective, leading to the ACIP’s decision not to recommend its usage. As such, healthcare providers must be judicious in their choice of influenza vaccine with their patients.



